IL3 and CD4+/CD56+ hematodermic neoplasm: Tagraxofusp, a CD123-directed cytotoxin that fuses recombinant human interleukin-3 with truncated diphtheria toxin, has shown clinical benefits in adult patients with untreated or relapsed BPDCN [2].